Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2576 of 2576 results for methods

  1. New NICE quality standard identifies improvements in UTI diagnosis for women

    Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.

  2. Non-invasive weight loss procedure can be an option to treat obesity

    A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.

  3. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  4. NICE's flexibility in evaluation of new health tech and fairer patient access

    Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.

  5. NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials

    James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.

  6. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.

  7. Additional evidence needed to assess histology-independent cancer drugs

    A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.

  8. NICE and NIHR: working together to produce research with impact

    Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.

  9. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  10. New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE

    People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.

  11. A 'safe space' for addressing complex health technology assessment challenges

    Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.